{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-25-000052","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2025-05-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.260009+00:00","generated_at":"2026-05-20T05:53:14.731459+00:00","sec_items":["2.05","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Keros ends PAH program, cuts 45% of staff, expects $17M annual savings","bullets":["TROPOS trial discontinued after pericardial effusion safety events; all cibotercept PAH development halted.","Workforce reduced ~45% to 85 employees; one-time severance charges of ~$3.2M in Q2 2025.","Annualized cost savings of ~$17M expected; restructuring substantially complete by Q4 2025.","Strategic alternatives review ongoing; preliminary update to be provided by June 9, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-25-000052","json":"https://secwatch.observer/filing/0001664710-25-000052.json","markdown":"https://secwatch.observer/filing/0001664710-25-000052.md","text":"https://secwatch.observer/filing/0001664710-25-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000052/0001664710-25-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000052/kros-20250528.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T05:53:14.731459+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9454fa0ffe76ab6ca9779167df7f16a070af1f78","claim":"Keros Therapeutics, Inc. announced a restructuring with charges of approximately $3.2 million (approximately 45%).","evidence_excerpt":"These plans were communicated to affected employees on May 29, 2025. The Company expects to incur one-time cash charges associated with the Reorganization of approximately $3.2 million related to employee severance payments and related costs, which are expected to be expensed in the second quarter of 2025. In addition, the Company has committed to pay one-time","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000052/0001664710-25-000052-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $3.2 million"},{"label":"Headcount","value":"approximately 45%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}